Showing results (1001-1010 of 1,842) with videos related to
Sort By:
Pageof 185
Journal of Managed Care & Specialty Pharmacy|March 28, 2017
Characterizing Health Care Utilization, Direct Costs, and Comorbidities Associated with Interstitial Cystitis: A Retrospective Claims AnalysisAmy Tung, Zsolt Hepp, Aasthaa Bansal, et al.Journal of Managed Care & Specialty Pharmacy|March 28, 2017
Economic Burden of Irritable Bowel Syndrome with Diarrhea: Retrospective Analysis of a U.S. Commercially Insured PopulationJessica L Buono, Kush Mathur, Amelia J Averitt, et al.Journal of Managed Care & Specialty Pharmacy|October 27, 2016
Evaluating the Impact of Sample Medication on Subsequent Patient AdherenceJanice L Pringle, Arnie Aldridge, Shannon M Kearney, et al.Journal of Managed Care & Specialty Pharmacy|December 28, 2016
Contemporary Trends in Oral Antiplatelet Agent Use in Patients Treated with Percutaneous Coronary Intervention for Acute Coronary SyndromeKibum Kim, Todd A Lee, Daniel R Touchette, et al.Journal of Managed Care & Specialty Pharmacy|November 25, 2016
Adherence to Disease-Modifying Therapies for Multiple SclerosisLucas Higuera, Caroline S Carlin, Sarah AndersonJournal of Managed Care & Specialty Pharmacy|November 25, 2016
Evaluation of Real-World Experience with Tofacitinib Compared with Adalimumab, Etanercept, and Abatacept in RA Patients with 1 Previous Biologic DMARD: Data from a U.S. Administrative Claims DatabaseJames Harnett, Robert Gerber, David Gruben, et al.Journal of Managed Care & Specialty Pharmacy|November 25, 2016
AMCP Partnership Forum: Navigating Innovations in Diabetes CareJournal of Managed Care & Specialty Pharmacy|November 25, 2016
Health Care Costs for Patients with Heart Failure Escalate Nearly 3-Fold in Final Months of LifeEngels N Obi, Jason P Swindle, Stuart J Turner, et al.Journal of Managed Care & Specialty Pharmacy|November 25, 2016
Determining Multiple Sclerosis Phenotype from Electronic Medical RecordsRichard E Nelson, Jorie Butler, Joanne LaFleur, et al.Journal of Managed Care & Specialty Pharmacy|November 25, 2016
Real-World Drug Costs of Treating Hepatitis C Genotypes 1-4 with Direct-Acting Antivirals: Initiating Treatment at Fibrosis 0-2 and 3-4Timothy A Bach, Kathy ZaikenPageof 185